2 Oct 2026, 18:56
Substantial Holders—
CUVCLINUVEL PHARMACEUTICALS LIMITED
Announcement history available from 1 August 2025
Fromto
2 Oct 2026, 08:57
Meetings & Governance—
1 Oct 2026, 11:18
Company Update—
24 Sept 2026, 08:19
Substantial Holders—
18 Sept 2026, 17:12
Meetings & Governance—
8 Sept 2026, 09:32
Company Update—
2 Sept 2026, 08:15
Substantial Holders—
27 Aug 2026, 12:33
Company AdministrationMS
27 Aug 2026, 12:28
Financial ResultsMS
27 Aug 2026, 12:26
Company Administration—
27 Aug 2026, 12:25
Company Administration—
27 Aug 2026, 12:24
Dividends & Distributions—
27 Aug 2026, 12:22
Financial ResultsMS
27 Aug 2026, 12:21
Financial ResultsMS
20 Aug 2026, 09:07
Presentations—
14 Aug 2026, 08:16
Substantial Holders—
12 Aug 2026, 09:12
Company Update—
30 July 2026, 08:57
Company UpdateMS
28 July 2026, 08:56
Company UpdateMS
27 July 2026, 08:48
Securities Administration—
23 July 2026, 09:11
Company UpdateMS
21 July 2026, 08:35
Securities Administration—
20 July 2026, 08:33
Company Administration—
13 July 2026, 08:34
Company UpdateMS
2 July 2026, 11:36
Company Administration—
16 June 2026, 09:06
Company AdministrationMS
2 June 2026, 09:26
Presentations—
7 May 2026, 11:45
Securities Administration—
28 Apr 2026, 08:50
Company AdministrationMS
27 Apr 2026, 08:42
Company UpdateMS
24 Apr 2026, 08:56
Company UpdateMS
17 Apr 2026, 09:04
Securities Administration—
13 Apr 2026, 08:50
Securities Administration—
13 Apr 2026, 08:49
Securities Administration—
13 Apr 2026, 08:18
Substantial Holders—
2 Apr 2026, 12:15
Company Update—
27 Mar 2026, 08:35
Company UpdateMS
20 Mar 2026, 08:30
Letters & AddressesMS
5 Mar 2026, 09:48
Company Administration—
26 Feb 2026, 09:58
Financial ResultsMS
26 Feb 2026, 09:55
Financial ResultsMS
26 Feb 2026, 09:54
Financial ResultsMS
19 Feb 2026, 09:04
Presentations—
2 Feb 2026, 08:30
Presentations—
15 Jan 2026, 09:11
Letters & Addresses—
12 Jan 2026, 08:42
Company UpdateMS
8 Jan 2026, 09:44
Company Update—
2 Jan 2026, 09:22
Securities Administration—
19 Dec 2025, 08:34
Company Update—
8 Dec 2025, 08:33
Company UpdateMS
| Date / Time | Heading | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 2 Oct 2026, 18:56 | Change in substantial holding | Substantial Holders | — | 02002 | |
| 2 Oct 2026, 08:57 | Notice of Annual General Meeting/Proxy Form | Meetings & Governance | — | 08001, 08004, 16002 | |
| 1 Oct 2026, 11:18 | New CUV105 vitiligo cases presented to EADV | Company Update | — | 11001 | |
| 24 Sept 2026, 08:19 | Becoming a substantial holder | Substantial Holders | — | 02001 | |
| 18 Sept 2026, 17:12 | CLINUVEL date of Annual General Meeting | Meetings & Governance | — | 08006 | |
| 8 Sept 2026, 09:32 | CLINUVEL develops proprietary ZEROKIN device | Company Update | — | 11001 | |
| 2 Sept 2026, 08:15 | Ceasing to be a substantial holder | Substantial Holders | — | 02003 | |
| 27 Aug 2026, 12:33 | CLINUVEL considers Nasdaq listing, ASX delisting | Company Administration | MS | 12008 | |
| 27 Aug 2026, 12:28 | Investor Presentation | Financial Results | MS | 03003, 03026 | |
| 27 Aug 2026, 12:26 | Appendix 4G | Company Administration | — | 03025 | |
| 27 Aug 2026, 12:25 | Corporate Governance Statement | Company Administration | — | 03024 | |
| 27 Aug 2026, 12:24 | Dividend/Distribution - CUV | Dividends & Distributions | — | 10001, 10002, 10003 | |
| 27 Aug 2026, 12:22 | A decade of profitability provides U.S. expansion foundation | Financial Results | MS | 03003 | |
| 27 Aug 2026, 12:21 | Appendix 4E and Annual Report to Shareholders 2026 | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020, 10001, 10003 | |
| 20 Aug 2026, 09:07 | CLINUVEL Annual Results - Investor Webinar | Presentations | — | 03027, 14014 | |
| 14 Aug 2026, 08:16 | Becoming a substantial holder | Substantial Holders | — | 02001 | |
| 12 Aug 2026, 09:12 | CLINUVEL's injectable peptide platform | Company Update | — | 11001 | |
| 30 July 2026, 08:57 | Commercial update on vitiligo | Company Update | MS | 11001 | |
| 28 July 2026, 08:56 | Update - SCENESSE in vitiligo | Company Update | MS | 11001 | |
| 27 July 2026, 08:48 | Notification of cessation of securities - CUV | Securities Administration | — | 06027 | |
| 23 July 2026, 09:11 | CLINUVEL strategic reorganisation to refocus on U.S. markets | Company Update | MS | 11001, 12008 | |
| 21 July 2026, 08:35 | CLINUVEL's ADS commences trading on Nasdaq | Securities Administration | — | 14011 | |
| 20 July 2026, 08:33 | CLINUVEL's ADS to commence trading on Nasdaq | Company Administration | — | 12008, 14011 | |
| 13 July 2026, 08:34 | SCENESSE approved for EPP in Canada | Company Update | MS | 11001 | |
| 2 July 2026, 11:36 | CLINUVEL confirms terms of CEO's Employment Agreement | Company Administration | — | 12008 | |
| 16 June 2026, 09:06 | CLINUVEL publicly files 20-F to U.S. SEC | Company Administration | MS | 12008 | |
| 2 June 2026, 09:26 | CLINUVEL US Non-Deal Roadshow Presentation | Presentations | — | 03026 | |
| 7 May 2026, 11:45 | Notification regarding unquoted securities - CUV | Securities Administration | — | 06021 | |
| 28 Apr 2026, 08:50 | CLINUVEL update on Level II ADR upgrade, Nasdaq uplist | Company Administration | MS | 12008 | |
| 27 Apr 2026, 08:42 | FDA relaxes SCENESSE postmarketing requirement | Company Update | MS | 11001 | |
| 24 Apr 2026, 08:56 | Final EMA scientific advice for pivotal Phase III vitiligo | Company Update | MS | 11001 | |
| 17 Apr 2026, 09:04 | Notification of cessation of securities - CUV | Securities Administration | — | 06027 | |
| 13 Apr 2026, 08:50 | Section 708A Cleansing Statement | Securities Administration | — | 06018 | |
| 13 Apr 2026, 08:49 | Application for quotation of securities - CUV | Securities Administration | — | 06020 | |
| 13 Apr 2026, 08:18 | Change in substantial holding | Substantial Holders | — | 02002 | |
| 2 Apr 2026, 12:15 | CLINUVEL reports highlights from AAD 2026 | Company Update | — | 11001 | |
| 27 Mar 2026, 08:35 | CLINUVEL's global programs showcased at AAD | Company Update | MS | 11001 | |
| 20 Mar 2026, 08:30 | Chair Letter to Shareholders | Letters & Addresses | MS | 16002 | |
| 5 Mar 2026, 09:48 | CLINUVEL Investor Webinar Half Year Results December 2025 | Company Administration | — | 12008 | |
| 26 Feb 2026, 09:58 | Half Year Results Presentation | Financial Results | MS | 03004, 03026 | |
| 26 Feb 2026, 09:55 | CLINUVEL Record Revenues, Advances Strategic Expansion | Financial Results | MS | 03004, 03014 | |
| 26 Feb 2026, 09:54 | Appendix 4D and Half Year Report | Financial Results | MS | 03004, 03009, 03010, 03015, 03019 | |
| 19 Feb 2026, 09:04 | CLINUVEL Investor Webinar | Presentations | — | 14014 | |
| 2 Feb 2026, 08:30 | Clinical & Financial Update | Presentations | — | 03026 | |
| 15 Jan 2026, 09:11 | Managing Director Letter to Shareholders | Letters & Addresses | — | 16002 | |
| 12 Jan 2026, 08:42 | CLINUVEL - injectable peptide platform in preclinical study | Company Update | MS | 11001 | |
| 8 Jan 2026, 09:44 | SCENESSE efficacy in vitiligo - new cases presented at RDTC | Company Update | — | 11001 | |
| 2 Jan 2026, 09:22 | Notification of cessation of securities - CUV | Securities Administration | — | 06027 | |
| 19 Dec 2025, 08:34 | CLINUVEL progresses Level II ADR upgrade, Nasdaq uplist | Company Update | — | 11001, 12008 | |
| 8 Dec 2025, 08:33 | CLINUVEL expands Singapore RD&I Centre | Company Update | MS | 11001 |
1–50 of 79
1 / 2